AVMXY News and Press, Avita Medical From 04/04/19

Additional data presented at ABA Annual meeting include results demonstrating that donor sites treated using the RECELL System could be reharvested in as little as seven days after treatment Patients with burns covering more than 50% of their bodies treated using the RECELL System in c...

DENVER, Colo., March 25, 2019- (24/7MarketNews via COMTEX)- Several companies that 24/7 Market News has featured are among the companies that hit new 52 week highs, for the trading week ending March 22, 2019. Anvia Holdings Corp (OTCQB:ANVV) has been advancing since it laid out its “corp...

We knew it had to end sometime. After four outstanding earnings day moves, including three gap-ups and third quarter 2018's spectacular +44% price explosion, on February 26, 2019, Vericel ( VCEL ) released its usual impressive 4th quarter earnings, and the stock price went... down. Hard. Inves...

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that management will present at the Cowen and Company 39th Annual Health Care Conference in Boston. The presentation is being made on 13 March 2019 from 11:20 a.m. to 11:50 a.m. EDT at the Boston Marrio...

Presentation describing treatment of pediatric patients with RECELL System selected as “Best of the Best Abstract” Developer of RECELL System, Professor Fiona Wood, to present long-term clinical outcomes of over 3,500 patients treated with RECELL AVITA Medical (ASX:...

COSMOTEC has filed a JPMDA application for approval to market the RECELL System in Japan AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it has collaborated with COSMOTEC, an M3 Group company, to market and distribute the RECELL® Aut...

-Sales temporarily interrupted while closing administrative and procedural open items related to EU certificates and unrelated to product performance -No impact on U.S. market AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that sal...

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, announced that it filed today with the ASX its Appendix 4D – Half-Year Report for the six months ended 31 December 2018. Revenues for First Six Months and Update on U.S. National Market Launch AV...

There are many biotechnology companies that manage to gain the excitement of investors with the next revolutionary advancement in medicine. In reality, however, most of these companies are often a long, long way off to proving they will ever make it to an FDA authorized Phase III trial, much l...

Avita Medical Ltd. ADR ( OTCQX:AVMXY ): Q2 Revenue of A$3.9M (+65.3% Y/Y) Press Release More news on: Avita Medical Ltd. ADR, Earnings news and commentary, Healthcare stocks news, ,